The FDA has approved a biosimilar of pertuzumab which is indicated for multiple breast cancer settings. The FDA has approved ...
Three new treatments for a specific type of breast cancer will remain excluded from basic health insurance coverage for now.
In patients with metastatic breast cancer, pre-treatment interstitial lung abnormalities (ILAs) and human epidermal growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback